Get the content you want anytime you want.
Association of Nurses in AIDS Care Conference (ANAC 2019)

Select coverage from Association of Nurses in AIDS Care Conference (ANAC 2019) is included below:

Challenges of Self-Managing HIV and Diabetes
Julie Zuñiga, PhD, RN, assistant professor at The University of Texas at Austin, shares findings from her research on self-management of the dual diagnosis of HIV and diabetes.
Improving Care for Criminalized Populations at Risk for HIV in Botswana
Several key populations with heightened risk for HIV face criminalization in Botswana. The Botswana Family Welfare Association targeted efforts to improve care for these key populations.
A Nurse-Driven Model to Facilitating Same-Day ART Initiation
Heather Alt, BSN, RN, ACRN, CPH, discusses research on a nurse-led model for same-day initiation of antiretroviral therapy for people newly diagnosed with HIV.
Exploring HIV Knowledge and Attitudes Among Adolescents in Uganda
Focus groups in 3 Mbarara schools identified adolescent knowledge, attitudes, and suggestions for HIV prevention in Uganda.
Can an 8 Week Treatment Eliminate HCV in Black Patients Co-Infected with HIV?
A retrospective review reveals that 8 weeks may be enough time to eliminate HCV in black patients co-infected with HIV, a population which faces barriers to longer treatment courses. 
Reducing HIV Transmission Among Black MSM Who Use Drugs
Black MSM who use drugs face substantial barriers to HIV treatment and prevention. A recent study analyzed their needs first-hand by conducting in-depth interviews. 
Expanding NP HIV Training Through the National HIV Curriculum
As HIV treatment shifts into primary care, it is important to educate NPs on HIV care and prevention in order to maintain recent gains towards ending the HIV epidemic.
Gaps Exist Between Perceived and Actual CVD Risk in People with HIV
Perceived and actual risk of cardiovascular disease is only weakly associated in people living with HIV. An analysis reveals that provider CVD risk discussion is significantly associated with perception of CVD susceptibility.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?